Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
https://www.zacks.com/stock/news/2241353/are-medical-stocks-lagging-adicet-bio-acet-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2241353
Mar 15, 2024 - Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
0
2seventy bio appoints Eli Casdin and Charles Newton to its board of directors
https://seekingalpha.com/news/4081841-2seventy-bio-appoints-eli-casdin-and-charles-newton-to-its-board-of-directors?source=feed_sector_healthcare
Mar 20, 2024 - 2seventy bio (TSVT) announces the appointment of Eli Casdin and Charles Newton to its board of directors.
0
Bayer-backed Boundless Bio sets terms for $100M IPO
https://seekingalpha.com/news/4082227-bayer-back-boundless-bio-sets-terms-for-100m-ipo?source=feed_sector_healthcare
Mar 21, 2024 - Bayer-backed Boundless Bio (BOLD), an oncology drug developer, has set terms for a proposed $100M initial public offering. Read more here.
0
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet
https://www.zacks.com/stock/news/2244067/wall-street-analysts-think-annovis-bio-anvs-could-surge-211-71-read-this-before-placing-a-bet?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2244067
Mar 21, 2024 - The mean of analysts' price targets for Annovis Bio (ANVS) points to a 211.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2244443/tela-bio-inc-tela-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2244443
Mar 21, 2024 - TELA Bio (TELA) delivered earnings and revenue surprises of -20.45% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
https://www.zacks.com/stock/news/2244747/adicet-bio-acet-loses-16-39-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=CS-ZC-FT-tale_of_the_tape|rsi-2244747
Mar 22, 2024 - The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
0
What Makes Instil Bio (TIL) a New Buy Stock
https://www.zacks.com/stock/news/2246872/what-makes-instil-bio-til-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2246872
Mar 27, 2024 - Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
Mustang Bio stock climbs 9% amid drug development update
https://seekingalpha.com/news/4085033-mustang-bio-stock-climbs-amid-drug-development-update?source=feed_sector_healthcare
Mar 28, 2024 - Mustang Bio (MBIO) stock rose 9% Thursday after the company said it was planning to expand testing of its oncology drug candidate MB-106 into autoimmune diseases. Read more here.
0
Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO
https://seekingalpha.com/news/4085101-bayer-backed-boundless-bio-stock-falls-after-100m-ipo?source=feed_sector_healthcare
Mar 28, 2024 - Bayer-backed Boundless Bio (BOLD) saw its shares drop 8% following a $100M initial public offering on Thursday. Read more here.
0
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
https://seekingalpha.com/article/4681344-nuvation-bio-strong-buy-off-acquisition-late-stage-lung-cancer-candidate?source=feed_tag_editors_picks
Mar 31, 2024 - Nuvation Bio's acquisition of taletrectinib, boosts market cap while ensuring years of independent funding with liquid assets. Read more on NUVB's prospects.
0